Please ensure Javascript is enabled for purposes of website accessibility

Why Sesen Bio Stock Is Soaring Today

By Keith Speights - Jan 25, 2021 at 11:37AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst is very bullish about the biotech stock.

What happened

Shares of Sesen Bio (SESN -3.17%) were soaring 10.9% higher as of 11:26 a.m. after rising as much as 19.4% earlier in the day. The big jump came after Canaccord analyst John Newman called Sesen "a must-own small-cap stock for 2021."

So what

Should investors buy this biotech stock because one analyst is bullish about it? Nope. However, it's always a good idea to understand why analysts like (or dislike) a given stock.

Man wearing coat and tie giving a thumbs up in front of a laptop

Image source: Getty Images.

In this case, Canaccord's Newman foresees two positive catalysts on the way for Sesen. He thinks that the U.S. Food and Drug Administration (FDA) will grant priority review for the company's Vicineum in treating nonmuscle invasive bladder cancer (NMIBC). Winning priority review would mean that the candidate could obtain approval within six months instead of the normal 10 months after the FDA accepts Sesen's application.

If Sesen does receive priority review for Vicineum, Newman anticipates that the biotech will win FDA approval for the drug in the third quarter of this year. He thinks the stock could rise to $5 per share, more than triple Sesen's closing price on Friday.

Is Newman's optimism warranted? Maybe. Sesen reported positive late-stage data for Vicineum in the NMIBC indication. There's a significant unmet need for high-risk NMIBC patients. Vicineum will be an important new treatment alternative if it wins FDA approval.

Now what

Sesen submitted its biologics license application (BLA) for Viceneum on Dec. 21, 2020. It shouldn't be long before the FDA makes its determination on priority review for the drug.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sesen Bio, Inc. Stock Quote
Sesen Bio, Inc.
SESN
$0.50 (-3.17%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.